Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Moderna (MRNA) Stock Price & Analysis
15,060 Followers
MRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.55 - $142.79
Previous Close$132.68
Volume2.72M
Average Volume (3M)3.84M
Market Cap
$50.85B
Enterprise Value$43.46B
Total Cash (Recent Filing)$8.60B
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)-8.5
Beta1.09
Next Earnings
Aug 01, 2024EPS Estimate
-$3.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.68
Shares Outstanding383,239,726
10 Day Avg. Volume4,410,918
30 Day Avg. Volume3,837,491
Standard Deviation0.26
R-Squared0.10
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.56
Price to Sales (P/S)7.22
Price to Cash Flow (P/CF)19.80
P/FCF Ratio27.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit20.17
Enterprise Value/Ebitda-13.24
Forecast
1Y Price Target
$130.29Price Target Upside-1.96% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Moderna News
PremiumStock Analysis & Ideas
Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy?
Bulls Say, Bears Say
Bulls Say
Financial HealthModerna's strong cash position and reaffirmation of sales targets reflect the company's financial stability and confidence in its continued growth trajectory.
Market ExpansionModerna is expanding its global presence with new contracts in Brazil and a forthcoming EU tender, potentially increasing its market share in the COVID vaccine sector.
Product PipelineModerna's diverse pipeline, including 45 programs in development and a promising Phase 3 CMV vaccine candidate, showcases the company's commitment to addressing a broad range of medical needs.
Bears Say
Company GuidanceSchott specifically noted their 2025 guidance change was due to an update in an mRNA contract.
Financial PerformanceTop-line revenue growth has continued to decline, posing a challenging profit and loss backdrop as operating expenses remain high.
Vaccine EfficacySecond season vaccine efficacy data is expected to show additional waning after patients have gone through a second RSV season without an additional dose.
---
Ownership Overview
15.98% Insiders
20.03% Mutual Funds
45.90% Other Institutional Investors
18.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $62.55 and its highest was $142.79 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 02, 2024. The company reported -$3.07 earnings per share for the quarter, beating the consensus estimate of -$3.557 by $0.487.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -$3.35.
How many shares outstanding does Moderna have?
Moderna has 383,239,720 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.07 in its last earnings report, beating expectations of -$3.557. Following the earnings report the stock price went up 12.677%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Flagship Pioneering Inc.. It holds Moderna’s shares valued at 1B.
---
Moderna Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$130.29 (-1.96% Downside)
$130.29 (-1.96% Downside)
Blogger Sentiment
Neutral
MRNA Sentiment 56%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.05%
12-Months-Change
Fundamentals
Return on Equity
-37.68%
Trailing 12-Months
Asset Growth
-30.66%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q1 2024
0:00 / 0:00
---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$130.29
▼(-1.96% Downside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
26/26 ratings generated profit
1 Year Average Return
+261.48%
assigned a buy rating 15 days ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +261.48% per trade.
---